Altered biomarkers for cardiovascular disease and inflammation in autoimmune Addison's disease - a cross-sectional studyEndocrinology in Charlottenburg, Berlin, Germany.
Oslo University Hospital, Oslo, Norway.
Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden.
Vestfold Hospital Trust, Tønsberg, Norway.
Haugesund Hospital, Haugesund, Norway.
Haugesund Hospital, Haugesund, Norway.
Stavanger University Hospital, Stavanger, Norway.
Sørlandet Hospital, Kristiansand, Norway.
Department of Medicine, Drammen Hospital, Vestre Viken Health Trust, Drammen, Norway.
Department of Endocrinology, Akershus University Hospital, Lørenskog, Norway.
Department of Endocrinology, Akershus University Hospital, Lørenskog, Norway.
Umeå University, Umeå, Sweden.
University Hospital North Norway, Tromsø, Norway; UiT Arctic University of Norway, Tromsø, Norway.
Karolinska Institutet, Stockholm, Sweden.
Innlandet Hospital Trust, Hamar, Norway.
Innlandet Hospital Trust, Hamar, Norway.
Sørlandet Hospital, Arendal, Norway.
University of Bergen, Bergen, Norway; Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden.
University of Bergen, Bergen Norway; Haukeland Hospital, Norway; Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden.
University of Bergen, Bergen Norway; Haukeland Hospital, Norway; Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2023 (English)In: European Journal of Endocrinology, ISSN 0804-4643, E-ISSN 1479-683X, Vol. 189, no 4, p. 438-447Article in journal (Refereed) Published
Abstract [en]
Objective: Increased prevalence of cardiovascular disease has been reported in autoimmune Addisons disease (AAD), but pathomechanisms are poorly understood.
Design: Cross-sectional study.
Methods: We compared serum levels of 177 cardiovascular and inflammatory biomarkers in 43 patients with AAD at >18-h glucocorticoid withdrawal and 43 matched controls, overall and stratified for sex. Biomarker levels were correlated with the frequency of adrenal crises and quality of life (QoL) by AddiQoL-30. Finally, we investigated changes in biomarker levels following 250 mu g tetracosactide injection in patients without residual adrenocortical function (RAF) to explore glucocorticoid-independent effects of high ACTH.
Results: Nineteen biomarkers significantly differed between patients with AAD and controls; all but 1 (ST1A1) were higher in AAD. Eight biomarkers were significantly higher in female patients compared with controls (IL6, MCP1, GAL9, SPON2, DR4, RAGE, TNFRSF9, and PGF), but none differed between male patients and controls. Levels of RAGE correlated with the frequency of adrenal crises (r = 0.415, P = .006) and AddiQoL-30 scores (r = -0.347, P = .028) but not after correction for multiple testing. PDL2 and leptin significantly declined 60 min after injection of ACTH in AAD without RAF (-0.15 normalized protein expression [NPX], P = .0001, and -0.25 NPX, P = .0003, respectively).
Conclusions: We show that cardiovascular and inflammatory biomarkers are altered in AAD compared with controls, particularly in women. RAGE might be a marker of disease severity in AAD, associated with more adrenal crises and reduced QoL. High ACTH reduced PDL2 and leptin levels in a glucocorticoid-independent manner but the overall effect on biomarker profiles was small.
Place, publisher, year, edition, pages
Bioscientifica, 2023. Vol. 189, no 4, p. 438-447
Keywords [en]
Autoimmunity, primary adrenal insufficiency, cardiovascular disease, proteomics, biomarkers
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-110346DOI: 10.1093/ejendo/lvad136ISI: 001086414300001PubMedID: 37807083Scopus ID: 2-s2.0-85180101346OAI: oai:DiVA.org:oru-110346DiVA, id: diva2:1819945
Funder
Novo Nordisk Foundation, NNF18OC0034130The Research Council of Norway, 288022Stockholm County CouncilKarolinska Institute
Note
Funding Agencies:
Research Council of Norway
Novo Nordisk Foundation
Internal Medicine Association of Norway
University of Bergen
Western Regional Health Authorities
Department of Medicine and Hormone Laboratory
Haukeland University Hospital
Stockholm County Council
Karolinska Institutet
2023-11-062023-12-152024-02-01Bibliographically approved